News Sentiment

NVNO sentiment intelligence

enVVeno Medical Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 11.36 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 59

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+2.3% over one week, +13.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

EnVVeno Medical : Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction 2.3% Price confirming higher
Trend fit Trend inactive 13.6% over four weeks
Fair value -89.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 44
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 59
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 16
TradingView 10
Stock Titan 9
ACCESS Newswire 5
StockStory 2
marketscreener.com 1
富途牛牛 1
Investing.com Nigeria 1

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 22
Regulatory and legal 6
Deals and strategy 3
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Stock Titan Direct company coverage

enVVeno's non-surgical valve trial gets first-ever FDA IDE approval

enVVeno Medical (NASDAQ: NVNO) announced that its CEO, Robert Berman, discussed recent milestones for the company's enVVe replacement venous valve system in a Virtual Investor "What This Means" segment. These milestones include the issuance of the first U.S. patent for the enVVe

Tone
Positive 71/100
Event
Regulatory and legal
Published
15 Jul 2026 12:43
Source
Stock Titan
ACCESS Newswire Direct company coverage

enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment

enVVeno Medical announced that CEO Robert Berman discussed the company's recent U.S. patent issuance in a Virtual Investor "What This Means" segment. This patent, combined with FDA IDE approval for its enVVe system, is expected to strengthen the company's competitive position in

Tone
Positive 74/100
Event
Regulatory and legal
Published
15 Jul 2026 08:30
Source
ACCESS Newswire
Stock Titan Direct company coverage

enVVeno Medical (NASDAQ: NVNO) releases updated investor presentation

enVVeno Medical Corporation (NASDAQ: NVNO) released an updated investor presentation on July 14, 2026, which will be used in meetings with investors and analysts. This presentation is furnished as Exhibit 99.1 under Regulation FD, ensuring that key information is made available t

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 20:41
Source
Stock Titan
TradingView Direct company coverage

Price to earnings forward of enVVeno Medical Corporation – BOATS:NVNO

This article briefly presents financial data for enVVeno Medical Corporation (NVNO) on the Blue Ocean Alternative Trade System (BOATS). It specifically highlights the "Price to earnings forward" metric. The content is primarily a data placeholder within a financial platform.

Tone
Neutral 50/100
Event
Earnings
Published
12 Jul 2026 02:40
Source
TradingView
TradingView Direct company coverage

NVNO Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for enVVeno Medical Corporation (NVNO) for 2027, based on analyst opinions. It includes current stock performance metrics, financial data such as earnings and revenue for recent quarters, and market capitalization. The article als

Tone
Negative 40/100
Event
Earnings
Published
09 Jul 2026 06:41
Source
TradingView
TradingView Direct company coverage

A42085 Forecast — Price Target — Prediction for 2027

This article provides an overview of enVVeno Medical Corporation (A42085) stock forecast, including a price target of 26.23 EUR from one analyst. It details the company's past earnings and revenue, noting a significant surprise in reported earnings and zero revenue for the last q

Tone
Negative 37/100
Event
Earnings
Published
08 Jul 2026 09:41
Source
TradingView
Investing.com Nigeria Direct company coverage

enVVeno Medical receives U.S. patent for venous valve system By Investing.com

enVVeno Medical Corporation (NASDAQ:NVNO) has been granted a U.S. patent for its enVVe transcatheter replacement venous valve system, which is designed to treat deep venous insufficiency. This patent covers key components of the system and methods for patient treatment. The compa

Tone
Positive 73/100
Event
Market update
Published
07 Jul 2026 20:43
Source
Investing.com Nigeria
News-Press NOW Direct company coverage

enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial

The article reports that enVVeno Medical has received a significant U.S. patent for its enVVe System, which is expected to bolster its competitive position. This development comes as the company prepares to launch a historic FDA pivotal trial. The patent is described as transform

Tone
Positive 95/100
Event
Market update
Published
07 Jul 2026 12:40
Source
News-Press NOW
Investing.com Direct company coverage

enVVeno Medical receives U.S. patent for venous valve system

enVVeno Medical has been granted a U.S. patent for its enVVe transcatheter replacement venous valve system, designed to treat deep venous insufficiency. The company is set to begin its TAVVE U.S. pivotal trial following FDA approval, with patient data expected by Q4 2026. Despite

Tone
Positive 74/100
Event
Regulatory and legal
Published
07 Jul 2026 12:40
Source
Investing.com
Stock Titan Direct company coverage

enVVeno patent covers key enVVe valve parts before pivotal FDA trial

enVVeno Medical (NASDAQ:NVNO) has been granted U.S. Patent No. 12,575,932, covering core components of its enVVe transcatheter replacement venous valve system. This patent strengthens the company's intellectual property ahead of the launch of its TAVVE U.S. pivotal trial, which a

Tone
Positive 72/100
Event
Market update
Published
07 Jul 2026 12:40
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of enVVeno Medical Corporation – NASDAQ:NVNO

This article provides a brief snapshot of the "Price to sales forward" metric for enVVeno Medical Corporation (NASDAQ: NVNO) as found on TradingView. It shows that there is no data available for the period, value, or change in this specific financial metric. The content primarily

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 14:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of enVVeno Medical Corporation – NASDAQ:NVNO

This article focuses on the enterprise value to revenue forward metric for enVVeno Medical Corporation, traded under the NASDAQ:NVNO symbol. It is presented within the context of financial data available on TradingView, indicating a specific financial analysis perspective for the

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 07:08
Source
TradingView
TradingView Direct company coverage

Price to sales forward of enVVeno Medical Corporation – FWB:5HJ0

This article provides financial information for enVVeno Medical Corporation (FWB:5HJ0) on the Frankfurt Stock Exchange, specifically focusing on its forward price-to-sales ratio. The content is primarily a data placeholder and navigational links from TradingView, offering no deta

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 04:08
Source
TradingView
TradingView Direct company coverage

Price to book forward of enVVeno Medical Corporation – FWB:5HJ0

The article title indicates a discussion about the "Price to book forward" for enVVeno Medical Corporation (FWB:5HJ0) listed on the Frankfurt Stock Exchange. However, the provided content only contains navigation, market data links, and copyright information, without any actual f

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 01:37
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of enVVeno Medical Corporation – NASDAQ:NVNO

This article provides financial information for enVVeno Medical Corporation (NASDAQ: NVNO), focusing on its forward price-to-earnings ratio. It appears to be a snapshot from a financial data platform, indicating the company's ticker, market, and a period value for the forward P/E

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 23:40
Source
TradingView
TradingView Direct company coverage

enVVeno Medical Corporation Actuals & Estimates (FWB:5HJ0)

This article provides financial actuals and estimates for enVVeno Medical Corporation (FWB:5HJ0), including income statement, balance sheet, and cash flow data. It details the company's stock ticker, historical price performance, upcoming earnings report date, net income, and emp

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 22:08
Source
TradingView
TradingView Direct company coverage

enVVeno Medical Corporation Actuals & Estimates (NASDAQ:NVNO)

This article provides an overview of enVVeno Medical Corporation (NASDAQ: NVNO), detailing its stock performance, financial data, and analyst estimates. It highlights the current stock price, historical highs and lows, volatility, market capitalization, and upcoming earnings repo

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 17:40
Source
TradingView
TradingKey Direct company coverage

enVVeno Medical Corp (NVNO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of enVVeno Medical Corp's (NVNO) shareholder structure, detailing major individual and institutional holders as well as shareholder types. It lists top shareholders like Satterfield (Thomas A Jr) and Perceptive Advisors LLC, alongside a breakdown

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 09:09
Source
TradingKey
Stock Titan Direct company coverage

Director at enVVeno Medical (NASDAQ: NVNO) sells 140 shares under Rule 10b5-1 plan

Francis Duhay, a director at enVVeno Medical Corp (NASDAQ: NVNO), sold 140 shares of common stock at $10.305 per share on June 11, 2026. This transaction was executed under a pre-planned Rule 10b5-1 trading plan established in June 2025. Following the sale, Duhay directly holds 2

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 20:09
Source
Stock Titan